BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Philadelphia Trial Results In Split Verdict; Wyeth (WYE) Prevails In One Case, While Jury Awards $41,000 In Compensatory Damages In Second Case


10/19/2005 5:11:55 PM

MADISON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Wyeth announced today that a jury reached a split verdict after deliberating in two cases in the Court of Common Pleas of the First Judicial District of Pennsylvania. In the first case, Julia Feagins v. Wyeth, the jury rendered a decision in favor of the Company in the damages phase of this bifurcated (two-phase) trial. The verdict ends this case without the need for the second phase of the trial regarding liability.

In the second case, Ida Dupree v. Wyeth, the jury found in favor of plaintiff in the amount of $41,195.12. Wyeth announced that it has waived the second phase of the trial, but will pursue post-trial motions and appellate options, if necessary.

"While the jury made the appropriate decision with regards to Ms. Feagins," says Bob Limbacher, an attorney representing Wyeth, "we do not believe the award for Ms. Dupree is consistent with the evidence presented and we plan to explore our post-trial and appellate options."

The verdicts came at the end of the first phase of a bifurcated (two-phase) trial that began on October 18, 2004 before The Honorable Norman Ackerman. The plaintiffs alleged heart valve injury from the use of the diet drug Pondimin, a drug once marketed by Wyeth.

Wyeth is one of the world's largest research-driven pharmaceutical and health care products companies. It is a leader in the discovery, development, manufacturing, and marketing of pharmaceuticals, vaccines, biotechnology products and nonprescription medicines that improve the quality of life for people worldwide. The Company's major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Wyeth

CONTACT: Lowell Weiner, +1-973-660-5013, or Justin Victoria,+1-973-660-5340, both of Wyeth; or Douglas Petkus, Wyeth Pharmaceuticals,+1-484-865-5140



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES